| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Earth Science Tech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Earth Science Tech, Inc. (ETST) Launches MyOnlineConsultation.com, Finalizing a Fully Vertically Integrated Telehealth and Pharmacy Ecosystem | 1 | GlobeNewswire (USA) | ||
| 13.03. | Earth Science Tech verlängert Verträge mit Finanz- und Technologievorstand um ein Jahr | 1 | Investing.com Deutsch | ||
| 13.03. | Earth Science Tech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Earth Science Tech GAAP EPS of $0.00 misses by $0.01, revenue of $8.4M misses by $3.05M | 2 | Seeking Alpha | ||
| EARTH SCIENCE TECH Aktie jetzt für 0€ handeln | |||||
| 17.02. | Earth Science Tech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Earth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 Million | 148 | GlobeNewswire (Europe) | Outlines strategic portfolio actions, governance enhancements and capital discipline plans to support next phase of growth MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST)... ► Artikel lesen | |
| 17.02. | Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued Expansion | 2 | GlobeNewswire (USA) | ||
| 09.02. | Earth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.01. | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Earth Science Tech reports Q2 results | 1 | Seeking Alpha | ||
| 12.11.25 | Earth Science Tech, Inc. Reports Strong Q2 Fiscal 2025 Results | 153 | GlobeNewswire (Europe) | MIAMI, FL, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling high-potential operating businesses... ► Artikel lesen | |
| 12.11.25 | Earth Science Tech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 19.08.25 | Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock | 258 | GlobeNewswire (Europe) | Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling high-potential businesses... ► Artikel lesen | |
| 08.08.25 | Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions | 196 | GlobeNewswire (Europe) | MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL - August 8, 2025 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling... ► Artikel lesen | |
| 27.06.25 | Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million | 206 | GlobeNewswire (Europe) | Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "Company"), a strategic holding company, focused on value creation through the acquisition, operational... ► Artikel lesen | |
| 06.05.25 | Earth Science Tech, Inc. Annual Shareholder Letter FY Ending 03/31/2025 | 195 | GlobeNewswire (Europe) | Miami, FL, May 06, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "Company"), a strategic holding company, focused on value creation through the acquisition, operational... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LB PHARMACEUTICALS | 26,570 | +4,52 % | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | ||
| NOVO NORDISK | 33,900 | +1,27 % | Novo Nordisk: Wegovy erhält EU-Zulassung für Lieferung ohne Kühlkette | Die Europäische Arzneimittelagentur EMA hat eine Aktualisierung der Produktinformation für Wegovy zugelassen, die es erlaubt, das Präparat bei der Auslieferung an Patienten bis zu 48 Stunden bei Temperaturen... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 2,030 | +1,50 % | Milestone Pharmaceuticals initiiert Real-World-Studie für PSVT-Medikament CARDAMYST | ||
| BRIGHT MINDS BIOSCIENCES | 89,61 | +5,20 % | Jefferies initiates Bright Minds stock with buy on epilepsy drug | ||
| KAZIA THERAPEUTICS | 9,435 | +5,54 % | Australia's Kazia pays research institute $1.4M for epigenetic platform, preclinical drug | ||
| ETON PHARMACEUTICALS | 27,120 | +4,11 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| OMNIAB | 1,460 | -0,68 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| TILRAY BRANDS | 5,810 | -1,02 % | Tilray Brands, Inc.: Tilray Expands Canadian Cannabis Portfolio with Launch of PORTAL, A New High Intensity Brand for the Experienced Consumer | TORONTO, April 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. company (Nasdaq: TLRY; TSX: TLRY) a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,400 | +1,62 % | TriSalus to present drug delivery data at radiology meeting | ||
| AQUESTIVE THERAPEUTICS | 4,150 | -0,95 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| INCYTE | 82,26 | -0,70 % | Adagene Inc.: Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) | Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical... ► Artikel lesen | |
| DOCMORRIS | 6,270 | 0,00 % | Wiener Startup Hello Inside startet Kooperation mit Online-Apotheke DocMorris | ||
| BRISTOL-MYERS SQUIBB | 49,240 | -0,05 % | Bristol Myers, Merck oder Jazz: Die besten Pharma-Aktien für die Quartalssaison | © Foto: Frank Rumpenhorst - dpaUS-Pharmaaktien haben den Markt zuletzt klar geschlagen - doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum... ► Artikel lesen | |
| ELI LILLY | 786,00 | +0,45 % | Eli Lilly scheitert am Comeback-Versuch | Die Eli Lilly-Aktie zeigt nach dem Rücksetzer weiterhin ein angespanntes charttechnisches Bild. Entscheidend bleibt, ob sich der Kursbereich um die langfristige Durchschnittslinie stabilisieren kann... ► Artikel lesen | |
| GALDERMA GROUP | 171,85 | +0,41 % | Galderma: Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra and Restylane in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause | New interim results from a six-month investigator-initiated trial (IIT) supported by Galderma, regarding the clinical sequencing of women in menopause, show the combination of Restylane Skinboosters... ► Artikel lesen |